Clinical Trials Browser

Phase 3 × Interventional × Platinum Compounds × Clear all

NCT07416474 2026-02-20

RC148 Plus Platinum-Based Chemotherapy vs Tislelizumab Plus Platinum-Based Chemotherapy for First-Line Squamous Non-Small Cell Lung Cancer (sqNSCLC)

Phase 3 Not yet recruiting

Carcinoma, Non-Small-Cell Lung

NCT04821778 2026-01-21

Chemoradiotherapy in Esophageal or Esophagogastric Junction Cancer

Phase 3 Recruiting

Gastrointestinal

Esophageal Neoplasms

NCT04821843 2026-01-21

Neoadjuvant Treatment Modalities in Esophageal Cancer

Phase 3 Recruiting

Gastrointestinal

Esophageal Neoplasms

NCT06216301 2025-12-17

LUNAR-2

Phase 3 Recruiting

Carcinoma, Non-Small-Cell Lung, Neoplasm Metastasis

NCT07251582 2025-11-26

LungTime-C02

Phase 3 Recruiting

Resectable Stage II-III Non-Small Cell Lung Cancer (NSCLC)

NCT07170995 2025-11-18

Phase III Study of SHR-8068 Combined With Adebrelimab and Chemotherapy Versus Tislelizumab Combined With Chemotherapy in the Treatment of Locally Advanced or Metastatic Non-small Cell Lung Cancer

Phase 3 Recruiting

Carcinoma, Non-Small-Cell Lung

NCT04906993 2025-09-09

Camrelizumab Combined With Famitinib Malate for Treatment of Recurrent/Metastatic Cervical Cancer

Phase 3 Active not recruiting

Uterine Cervical Neoplasms

NCT05607550 2025-06-22

Study to Compare Furmonertinib to Platinum-Based Chemotherapy for Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC) With Epidermal Growth Factor Receptor (EGFR) Exon 20 Insertion Mutations (FURVENT)

Phase 3 Active not recruiting

Carcinoma, Non-Small-Cell Lung

NCT02891824 2025-02-11

ATALANTE

Phase 3 Completed

Ovarian Neoplasms

NCT05338970 2025-01-31

HERTHENA-Lung02: A Study of Patritumab Deruxtecan Versus Platinum-based Chemotherapy in Metastatic or Locally Advanced EGFRm NSCLC After Failure of EGFR TKI Therapy

Phase 3 Active not recruiting

Nonsquamous Non-small Cell Lung Cancer

NCT04428333 2024-10-09

INDUCE-4

Phase 3 Terminated

117 enrolled 33 charts

Squamous Cell Carcinoma of Head and Neck, Head and Neck Neoplasms

NCT06485557 2024-07-03

A Prospective Cohort Study of Neoadjuvant Chemotherapy Plus Sintillumab in the Treatment of Resectable NSCLC

Phase 3 Not yet recruiting

Resectable Non-small Cell Lung Cancer